Compare VanEck Semiconductor ETF (SMH) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs 10X Genomics Inc — how do they compare? VanEck Semiconductor ETF trades at $603.71 (market cap $73.92B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: VanEck Semiconductor ETF is far larger — about 7.3× 10X Genomics Inc's market cap, and VanEck Semiconductor ETF is more actively traded (11,050,892 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and 10X Genomics Inc for 91 Days on average.
| SMH | TXG | |
|---|---|---|
Market Cap | $73.92B | $10.07B |
Volume | 11,050,892 | 5,657,286 |
52-Week High | $668.91 | $97.74 |
52-Week Low | $325.10 | $11.48 |
Typical Hold Time | 101 Days | 91 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH trades at $603.33, down 3.47% on the day, but maintains a bullish technical outlook with strong moving average support. The semiconductor ETF has delivered exceptional returns, up approximately 69% year-to-date through September 30, 2026, significantly outperforming the broader market. Recent sector strength is driven by AI demand and positive industry developments, including AMD's $8.2 billion acquisition of World Labs.
The semiconductor sector's structural growth, particularly in AI applications, supports continued upside potential. However, concentration risk in top holdings like Nvidia and sensitivity to US-China trade tensions present meaningful headwinds. Current technical levels suggest support at $597 with resistance at $620, providing clear near-term trading parameters.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
